

# Asymmetric Fluorolactonization with a Bifunctional Hydroxyl **Carboxylate Catalyst**

Hiromichi Egami, Junshi Asada, Kentaro Sato, Daisuke Hashizume, Yuji Kawato, and Yoshitaka Hamashima\*,†

Supporting Information


ABSTRACT: We report the first successful example of a highly enantioselective fluorolactonization with an electrophilic fluorinating reagent, Selectfluor®, in the presence of a novel bifunctional organocatalyst. The catalyst design includes a carboxylate anion functioning as a phase-transfer agent and a benzyl alcohol unit to capture the substrate through hydrogen bonding. Fluorinated isobenzofuranones were obtained in good yields with up to 94% ee (97:3 er). On the basis of mechanistic studies, we propose a unique reaction mechanism with potential for further applications.

lthough fluorine is the 13th most abundant element on A lathough muorine is the 15th martin fluorine atom(s). However, artificial organofluorine compounds have found widespread applications in pharmaceuticals, agrochemicals, and fine chemicals as well as in materials science. Thus, the development of efficient methods to synthesize chiral fluorinated compounds is highly desirable.2 In this context, catalytic asymmetric fluorofunctionalization of alkenes would be a powerful method to obtain structurally diverse fluorinated compounds for structure-activity relationship studies. However, such reactions remain largely unexplored, with only a few exceptions that require a stoichiometric amount of chiral source.

In 2011, Toste and co-workers reported a conceptually new approach in which a chiral phosphate anion acts as an anionic phase-transfer catalyst to bring a reactive electrophilic fluorinating reagent, Selectfluor® (1),4 which is insoluble in nonpolar solvents, into the liquid phase, thereby suppressing the undesired background reaction to give the racemic product (Scheme 1a). Although further applications were reported, of this strategy is effective only for reactions of alkenes with noncharged pronucleophiles such as amides and is not applicable to alkenes bearing anionic nucleophiles. We envisaged that various types of fluorinated analogues of medicinally important heterocycles could be synthesized in a single step if acidic pronucleophiles such as carboxylic acids, sulfonamides, and phenols were available as pendant nucleophiles.

Following our work on bromolactonization, we became interested in asymmetric fluorolactonization of ene-carboxylic acids. While a variety of asymmetric halolactonization reactions

Scheme 1. Asymmetric Fluorodifunctionalizations of C-C **Double Bonds** 



with heavier halogens (Cl+, Br+, I+) have recently been developed, fluorolactonization had not been reported in either a stoichiometric or a catalytic version before we started the project. Since isobenzofuranone derivatives are found in various bioactive compounds,9 we selected the fluorination of ovinylbenzoic acid derivatives 2 as a model reaction (Scheme 1b). 10 Herein we report the first successful example of a highly enantioselective fluorolactonization catalyzed by a newly developed bifunctional organocatalyst.

Although the basic concept of anionic phase-transfer catalysis seemed promising for our purpose, we were aware that simple application of chiral phosphate anion catalysts might be difficult for the following reasons. First, the substrate carboxylate anion generated under basic phase-transfer conditions can act as an achiral phase-transfer catalyst to promote the undesired racemic reaction (Figure 1a). Second, either flexible ion pairing of the substrate anion with Selectfluor® or loose salt bridging between the catalyst and the substrate anion would result in low asymmetric induction (Figure 1b). In accord with these considerations, a representative phosphoric acid (TRIP), which gave high enantioselectivity in the fluorocyclization of allylic amides, 5, experiments. 11 was found to be almost ineffective in our initial

Received: June 24, 2015 Published: August 7, 2015

<sup>&</sup>lt;sup>†</sup>School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka 422-8526, Japan

<sup>\*</sup>Materials Characterization Support Unit, RIKEN Center for Emergent Matter Science, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan




Figure 1. (a, b) Problems in the development of fluorolactonization reactions and (c) synthesis of our catalyst.

To overcome the possible problems illustrated in Figure 1a,b, the catalyst is required not only to transport 1 efficiently to the liquid phase but also to undergo an associative interaction with the anionic substrate. Therefore, the catalyst should be equipped with an anion to form an ion pair with 1 and a hydrogen-bond donor to fix the substrate anion. Because we had observed in our early experiments that the substrate 2 acts as a phase-transfer catalyst precursor (vide infra) and because various synthetic methods are available to introduce a carboxyl group into binaphthol, we selected a carboxylate anion as a key functionality. As a hydrogen-bond donor, we planned to install a hydroxyl group. These considerations led us to design the novel bifunctional precatalysts 5 (Figure 1c). Even though these catalysts are equivalent to the substrate anion in terms of electronic charge, we assumed that better transport of 1 would be achieved by increasing the hydrophobicity of the catalyst, thereby minimizing the background reaction promoted by the substrate anion. Consequently, we expected that catalyst 5 would form a ternary complex by accommodating both 1 and the substrate into the chiral pocket. To test our hypothesis, we synthesized a series of novel catalysts 5 on a multigram scale from C2-symmetric dicarboxylic acids 4, which were originally developed by Maruoka et al.,12 via monoesterification13 followed by reduction with LiAlH<sub>4</sub>. 11

These catalyst precursors were evaluated for fluorolactonization of 2a (Table 1). As the size of the substituent increased, the catalyst efficiency greatly improved (entries 1-3). To our delight, 3a was obtained in 84% yield with 83% ee when 5c was used as a precatalyst (entry 3). Further optimization revealed that the combination of Na<sub>3</sub>PO<sub>4</sub> as a base<sup>14</sup> and Na<sub>2</sub>SO<sub>4</sub> as a dehydrating agent in cyclohexane gave the best results (entry 9). This fluorolactonization was successfully scaled up without difficulty (entry 10). Interestingly, the reaction with Selectfluor® II gave a lower enantioselectivity (entry 12). As illustrated in Figure 1a, the reaction without precatalyst 5 also proceeded to give racemic 3a in 51% yield (entry 13).


Having established the optimum reaction conditions, we next examined the generality of the reaction (Table 2). Various aryl-

Table 1. Optimization of the Reaction Conditions<sup>a</sup>

entry	precatalyst	solvent	base	yield (%) <sup>b</sup>	ee (%)
1	5a	toluene	Na <sub>3</sub> PO <sub>4</sub>	30	33
2	5b	toluene	$Na_3PO_4$	37	68
3	5c	toluene	$Na_3PO_4$	84	83
4	5c	toluene	$K_3PO_4$	44	18
5	5c	toluene	$K_2CO_3$	78	45
6	5c	toluene	$Na_2CO_3$	quant	59
7	5c	n-hexane	$Na_3PO_4$	77	87
8	5c	c-hexane	$Na_3PO_4$	85	88
$9^c$	5c	c-hexane	$Na_3PO_4$	quant (99) <sup>d</sup>	88
$10^{c,e}$	5c	c-hexane	$Na_3PO_4$	80 <sup>d</sup>	88
$11^{c,f}$	5c	c-hexane	$Na_3PO_4$	64	90
$12^g$	5c	c-hexane	$Na_3PO_4$	80	67
13	_	c-hexane	$Na_3PO_4$	51	_

<sup>a</sup>The reactions were carried out with precatalyst 5, 1, and the base in 1 mL of the solvent on a 0.1 mmol scale, unless otherwise noted. <sup>b</sup>Determined by <sup>1</sup>H NMR analysis using dibromoethane as an internal standard. <sup>c</sup>Run with Na<sub>2</sub>SO<sub>4</sub>. <sup>d</sup>Isolated yield. <sup>e</sup>Run on a 0.5 mmol scale. FRun at 15 °C. Run with Selectfluor® II instead of 1.

Table 2. Substrate Scope<sup>a</sup>



<sup>a</sup>The reactions were run on a 0.1 mmol scale, unless otherwise noted <sup>b</sup>Run for 48 h on a 0.5 mmol scale.

substituted vinylbenzoic acids underwent the fluorination reaction efficiently to give the desired fluorinated isobenzofuranons 3 in a highly enantioselective manner. A single recrystallization gave optically pure 3d (>99% ee), and X-ray analysis revealed its absolute stereochemistry to be R. In addition, the reaction was applicable to some alkyl-substituted substrates, and the reactions proceeded with good enantioselectivity (3m, 3n).

During the course of the catalyst screening, we were able to confirm the importance of the primary hydroxyl group within the catalyst. With 5b as the reference precatalyst, we examined the catalytic ability of structurally analogous precatalysts 6-8 (Scheme 2). While 5b gave fluorolactone 3a with 68% ee in

Scheme 2. Fluorolactonization with Other Analogous Acids as Precatalysts

toluene, only negligible asymmetric induction was observed in the reactions using precatalysts 6-8 under identical conditions. These results clearly indicate that the presence of a primary hydroxyl group at an appropriate position is important to achieve high asymmetric induction.

To gain further information regarding the reaction mechanism, NMR experiments were performed in toluene- $d_8$ , as toluene also gave good results (Table 1, entry 3). Selectfluor® (1) was not detected by ¹H NMR or ¹9F NMR spectroscopy even in the presence of inorganic salts (Na<sub>3</sub>PO<sub>4</sub> and Na<sub>2</sub>SO<sub>4</sub>). These results indicate that 1 is insoluble in toluene- $d_8$  and exclude the possibility that the inorganic salts function as phase-transfer agents.

Upon treatment of 5c with Na<sub>3</sub>PO<sub>4</sub> (5 equiv), peaks characteristic of 5c disappeared and broad signals were observed in the <sup>1</sup>H NMR spectrum, suggesting that the carboxylate anion catalyst forms aggregates. Interestingly, when an equimolar amount of 2a was added to this mixture, a set of sharp peaks appeared again. 11 This observation suggests that the substrate interferes with aggregation of the catalyst, forming a 1:1 complex 9 (Figure 2). Upon addition of 1 to this mixture, a characteristic peak at 50.9 ppm, which could be attributed to the N<sup>+</sup>-F unit of 1, <sup>16</sup> appeared in the <sup>19</sup>F NMR spectrum in addition to peaks of  $BF_4^-$  (-156.1 and -156.2 ppm). 11,16 Although these signals cannot be assigned at present, this observation strongly suggests that the catalyst forms the putative ion pair with 1.

On the basis of these observations, we propose the following reaction mechanism (Figure 2). The acid 5 tends to aggregate after deprotonation, but the substrate facilitates dissociation to give binary complex 9 consisting of the catalyst and the substrate. This complex may be responsible for the better transport of 1 compared with that by the catalyst aggregate because the N<sup>+</sup>-F unit was not detected in the absence of 2.<sup>11</sup> Then 9 reacts with 1 to generate the active fluorinating species 10 in the liquid phase. Since a positive nonlinear correlation was observed between the ee of the product and that of the catalyst, 11 we speculate that two catalyst molecules may be involved in the fluorination step (10,  $X^- = 5^-$  or  $9^-$ ). However, we cannot rule out the possibility that the observed




Figure 2. Proposed catalytic cycle.

nonlinear effect is due to pre-equilibration between the actual catalyst and the catalyst aggregate and that a ternary complex 10 ( $X^- = 2^-$  or  $BF_4^-$ ) might be operative. Fluorine is delivered to the substrate, affording intermediate 11 with release of fluorolactone 3. The ion exchange reaction, followed by association with the substrate anion, would complete the catalytic cycle. Taking into account the results shown in Scheme 2, it is likely that the hydroxyl group within 5c plays a key role in the interaction with the substrate. The hydroxyl group might also participate in hydrogen-bond formation with the neighboring carboxylate anion to fix its position. The high enantioselectivity observed in our reaction indicates that the catalyst-controlled reaction is much faster than the substratemediated reaction, presumably because of the high phasetransfer ability arising from the hydrophobic environment and the presence of polar functionalities.

In summary, we have presented the first successful example of catalytic asymmetric fluorolactonization using a newly designed anionic phase-transfer catalyst having a hydrogenbond donor site. Fluorolactonization of o-vinylbenzoic acids proceeded smoothly to give the corresponding fluorinated isobenzofuranones in good yields with high to excellent enantioselectivities. Experiments using structural analogues of 5 indicated that the combination of a carboxylate anion with a benzyl alcohol moiety is essential for high asymmetric induction. NMR experiments supported our hypothesis that the catalyst holds the substrate anion and a cationic fluorinating reagent in a chiral pocket. We consider this type of unsymmetrical bifunctional catalyst to have great potential for the synthesis of enantioenriched fluorinated compounds. Further studies are underway.

#### ASSOCIATED CONTENT

## S Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/jacs.5b06546.

> Detailed experimental procedures and spectroscopic data for product characterization (PDF)

Crystallographic data for 3d (CIF)

Crystallographic data for S7 (CIF)

#### AUTHOR INFORMATION

#### **Corresponding Author**

\*hamashima@u-shizuoka-ken.ac.jp

#### **Notes**

The authors declare no competing financial interest.

#### ACKNOWLEDGMENTS

This work was supported by a Grant-in-Aid for Scientific Research on Innovative Areas "Advanced Molecular Transformations by Organocatalysts," a research grant from Astellas Foundation for Research on Metabolic Disorders, and a grant for Platform for Drug Discovery, Informatics and Structural Life Science from MEXT and AMED.

### REFERENCES

- (1) (a) Kirsch, P. Modern Fluoroorganic Chemistry: Synthesis, Reactivity, Applications, 2nd ed.; Wiley-VCH: Weinheim, Germany, 2013. (b) Ojima, I. Fluorine in Medicinal Chemistry and Chemical Biology; Wiley-Blackwell: Oxford, U.K., 2009. (c) Gouverneur, V.; Müller, K. Fluorine in Pharmaceutical and Medicinal Chemistry: From Biophysical Aspects to Clinical Applications; Imperial College Press: London, 2012. (d) Müller, K.; Faeh, C.; Diederich, F. Science 2007, 317, 1881–1886.
- (2) (a) Lin, G.-Q.; You, Q.-D.; Cheng, J.-F. Chiral Drugs: Chemistry and Biological Action; John Wiley & Sons: Hoboken, NJ, 2011. (b) Liang, T.; Neumann, C. N.; Ritter, T. Angew. Chem., Int. Ed. 2013, 52, 8214–8264. (c) Yang, X.; Wu, T.; Phipps, R. J.; Toste, F. D. Chem. Rev. 2015, 115, 826–870.
- (3) (a) Shibata, N.; Suzuki, E.; Asahi, T.; Shiro, M. J. Am. Chem. Soc. 2001, 123, 7001–7009. (b) Wang, M.; Wang, B. M.; Shi, L.; Tu, Y. Q.; Fan, C.-A.; Wang, S. H.; Hu, X. D.; Zhang, S. Y. Chem. Commun. 2005, 41, 5580–5582. (c) Kong, K.; Feige, P.; de Haro, T.; Nevado, C. Angew. Chem., Int. Ed. 2013, 52, 2469–2473. (d) Wilkinson, S. C.; Lozano, O.; Schuler, M.; Pacheco, M. C.; Salmon, R.; Gouverneur, V. Angew. Chem., Int. Ed. 2009, 48, 7083–7086. (e) Wolstenhulme, J. R.; Rosenqvist, J.; Lozano, O.; Ilupeju, J.; Wurz, N.; Engle, K. M.; Pidgeon, G. W.; Moore, P. R.; Sandford, G.; Gouverneur, V. Angew. Chem., Int. Ed. 2013, 52, 9796–9800.
- (4) (a) Banks, R. E. J. Fluorine Chem. **1998**, 87, 1–17. (b) Nyffeler, P. T.; Durón, S. G.; Burkart, M. D.; Vincent, S. P.; Wong, C.-H. Angew. Chem., Int. Ed. **2005**, 44, 192–212.
- (5) Rauniyar, V.; Lackner, A. D.; Hamilton, G. L.; Toste, F. D. Science **2011**, 334, 1681–1684.
- (6) (a) Phipps, R. J.; Hiramatsu, K.; Toste, F. D. J. Am. Chem. Soc. 2012, 134, 8376–8379. (b) Phipps, R. J.; Toste, F. D. J. Am. Chem. Soc. 2013, 135, 1268–1271. (c) Wu, J.; Wang, Y.-M.; Drljevic, A.; Rauniyar, V.; Phipps, R. J.; Toste, F. D. Proc. Natl. Acad. Sci. U. S. A. 2013, 110, 13729–13733. (d) Zi, W.; Wang, Y.-M.; Toste, F. D. J. Am. Chem. Soc. 2014, 136, 12864–12867. (e) Romanov-Michailidis, F.; Guénée, L.; Alexakis, A. Angew. Chem., Int. Ed. 2013, 52, 9266–9270. (7) (a) Ikeuchi, K.; Ido, S.; Yoshimura, S.; Asakawa, T.; Inai, M.; Hamashima, Y.; Kan, T. T. Org. Lett. 2012, 14, 6016–6019. (b) Kawato, Y.; Ono, Y.; Kubota, A.; Egami, H.; Hamashima, Y.
- (8) (a) Denmark, S. R.; Kuester, W. E.; Burk, M. T. *Angew. Chem., Int. Ed.* **2012**, *51*, 10938–10953. (b) Cheng, Y. A.; Yu, W. Z.; Yeung, Y.-Y. *Org. Biomol. Chem.* **2014**, *12*, 2333–2343.

Org. Lett. 2015, 17, 1244-1247.

(9) (a) Yoganathan, K.; Rossant, C.; Ng, S.; Huang, Y.; Butler, M. S.; Buss, A. D. J. Nat. Prod. 2003, 66, 1116—1117. (b) Logrado, L. P. L.; Santos, C. O.; Romeiro, L. A. S.; Costa, A. M.; Ferreira, J. R. O.; Cavalcanti, B. C.; Manoel de Moraes, O.; Costa-Lotufo, L. V.; Pessoa, C.; dos Santos, M. L. Eur. J. Med. Chem. 2010, 45, 3480—3489. (c) Hirai, G.; Ohkubo, M.; Tamura, Y.; Sodeoka, M. Bioorg. Med. Chem. Lett. 2011, 21, 3587—3590. (d) Lan, W.-J.; Liu, W.; Liang, W.-L.; Xu, Z.; Le, X.; Xu, J.; Lam, C.-K.; Yang, D.-P.; Li, H.-J.; Wang, L.-Y. Mar. Drugs 2014, 12, 4188—4199.

- (10) Parmar, D.; Maji, M. S.; Rueping, M. Chem. Eur. J. 2014, 20, 83–86.
- (11) See the Supporting Information.
- (12) Hashimoto, T.; Kimura, H.; Nakatsu, H.; Maruoka, K. J. Org. Chem. 2011, 76, 6030-6037.
- (13) Furuta, T.; Nikaido, M.; Yamamoto, J.; Kuribayashi, T.; Kawabata, T. Synthesis **2013**, 45, 1312–1318.
- (14) Among the inorganic bases examined, Na<sub>3</sub>PO<sub>4</sub> gave the best selectivity. According to the recent report by Rueping, <sup>10</sup> carbonate anion can mediate phase transfer of 1 in *n*-hexane, suggesting that the decreased ee value may be due to the background reaction promoted by Na<sub>2</sub>CO<sub>3</sub> (Table 1, entry 6).
- (15) Other cases where the reaction was unsatisfactory are given in the Supporting Information.
- (16) (a) Dolbier, W. R., Jr. Guide to Fluorine NMR for Organic Chemists; John Wiley & Sons: Hoboken, NJ, 2009. (b) Stabver, S.; Zupan, M. Acta Chim. Slov. 2005, 52, 13–26. (c) Finze, M.; Bernhardt, E.; Zähres, M.; Willner, H. Inorg. Chem. 2004, 43, 490–505.